Skip to main content
main-content

Chronic kidney disease


Browse the latest news, expert commentary, and educational content on chronic kidney disease.


Highlights

17-03-2021 | Dapagliflozin | News

Dapagliflozin may have primary prevention role for HF, renal outcomes

Post-hoc analysis of the primary prevention subgroup of DECLARE-TIMI 58 suggests that treatment with dapagliflozin may reduce the risk for first heart failure and renal events.

22-02-2021 | Canagliflozin | News

Antihypertensive effect for canagliflozin in diabetic renal disease

The SGLT2 inhibitor canagliflozin reduces blood pressure and the need for additional antihypertensives in people with type 2 diabetes and chronic kidney disease, research suggests.

05-01-2021 | Heart failure | News

Support for fluid reduction mechanism underlying SGLT2 inhibitor cardiorenal benefits

The SGLT2 inhibitor empagliflozin reduces estimated extracellular volume and plasma volume in patients who have heart failure with reduced ejection fraction, shows a randomized trial.

More on chronic kidney disease

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits